Ivabradina Generis (Ivabradine Hydrochloride)

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, which is responsible for spontaneous pacemaker activity. By inhibiting this current, the drug slows the rate of depolarisation, leading to a lower heart rate without affecting the strength of cardiac contraction.

The dose of Ivabradina Generis is determined individually by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and any concomitant therapies. The prescriber will set the appropriate strength and dosing schedule.

Safety of ivabradine in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting contractility or blood pressure. Beta‑blockers act on adrenergic receptors and have broader cardiovascular effects, which may be contraindicated or less tolerated in some patients.

Store Ivabradina Generis at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Ivabradina Generis is taken orally, usually with a glass of water. The exact timing (e.g., with or without food) and frequency are determined by the prescribing clinician based on the individual treatment plan.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and syncope. Patients should be monitored for signs of excessively low heart rate or arrhythmias, and therapy should be adjusted or discontinued if these events occur.

Ivabradina Generis should be avoided in patients with severe hepatic impairment, uncontrolled hypotension, acute decompensated heart failure, or those taking strong CYP3A4 inhibitors or other bradycardic agents that could cause excessive heart‑rate reduction.